Network Insights Methodology Whitepaper Get Access

Novo Nordisk

ORG Health Care / Pharmaceuticals Momentum 7.9ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$77B market cap (Copenhagen) manufactures insulin, GLP-1 agonists, and obesity therapeutics. Wegovy tablet approval push in China follows oral semaglutide dominance in US and European weight-loss markets; Q1 2026 obesity care revenue grew 35% YoY.

Pursuing regulatory approval to commercialize Wegovy (semaglutide) tablet formulation in China market; expansion of GLP-1 agonist portfolio in high-growth Asian markets.
0.14
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
7.9
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
20
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Novo Nordisk is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
FDA China Eli Lilly PlocamiumAI United States India Canada OpenAI AstraZeneca CEO Americans European Union Samsung Merck Bloomberg
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-22 2026-06-21 22 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
262.443
Sentiment-Momentum Divergence
0.000
Source Concentration
0.333
Signal
Novo Nordisk is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #29 of 85 in Health Care — in line with sector peers. PSI up 0.28 from yesterday (-0.15 -> 0.14).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
29 of 85
Sector Rank
+0.67
Peer Z-Score
67%
Sector Percentile
Network Analysis
20 Degree Centrality
Ego Network (top connections)
FDA (weight 26.0)China (weight 18.0)Eli Lilly (weight 16.0)PlocamiumAI (weight 10.0)United States (weight 10.0)India (weight 8.0)Canada (weight 6.0)OpenAI (weight 4.0) FDAChinaEli LillyPlocamiumAIUnited StatesIndiaCanadaOpenAI Novo Nordisk (degree 20) Novo Nordisk
Centrality History
2026-05-22 2026-06-21 22 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 26 NEW
China 18 NEW
Eli Lilly 16 NEW
PlocamiumAI 10 NEW
United States 10 NEW
India 8 NEW
Canada 6 NEW
OpenAI 4 NEW
AstraZeneca 4 NEW
CEO 3 NEW
Americans 3 NEW
European Union 3 NEW
Samsung 2 NEW
Merck 2 NEW
Bloomberg 2 NEW
Wall Street 2 NEW
Reuters 2 NEW
Netflix 2 NEW
Investing.com 2 NEW
Pfizer 1 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-21 ← Intelligence Network